Anti-cancer Drug Design

Anti-cancer drug design involving complexes of amino-acids and metal ions. D. R. Williams, Inorg. Chim. Acta, Rev.. 1972, 6,123-133 (96). [Pg.65]

L. K. Mehta, H. Monney, J. Parrick, and R. J. Hodgkiss, Anti-Cancer Drug Design, 1995, 10, 227. [Pg.999]

Crooke, R.M., In vitro toxicology and pharmacokinetics of antisense oligonucleotides, Anti-Cancer Drug Design, 1991, 6, 609-646. [Pg.16]

Zaludova, R., Natile, G. and Brabec, V., Anti-Cancer Drug Design, 12 (1997) 295. [Pg.207]

A. Villanueva, A. Juarranz, V. Diaz, J. Gomez and M. Canete, Anti-Cancer Drug Design, 1992, 7, 297-303. [Pg.228]

Richter A, Kociebski P, Raubo P, Davies DA (1997) Anti-Cancer Drug Design 12 217... [Pg.241]

Schott H, Schwendener RA. Synthesis and structure-activity studies in vivo of liposomal phospholipid-N -palmitoyl- and N" -hexadecyl-l-P-D-arabinofurano-sylcytosine conjugates. Anti-Cancer Drug Design 1996 11 451. [Pg.61]

Kelly JM, Feeney MM, Tossi AB, Lecomte JP, Kirsch-De Mesmaeker A (1990) Anti-Cancer Drug Design 5 69... [Pg.73]

Keskin O, Bahar I, Jernigan RL et al. Characterization of anti-cancer agents by their growth inhibitory activity and relationships to mechanism of action and structure. Anti-Cancer Drug Design 2000 15 79-98. [Pg.71]

Stevenson, G. T., Pindar, A, and Slade, C J. (1989) A chimeric antibody with dual Fc regions (bisFabFc) prepared by manipulations at the IgG hinge. Anti-Cancer Drug Design 3, 219-230... [Pg.133]

Barrows LR, Radisky DC, Copp BR, Swaffar DS, Kramer RA, Warters RL, Ireland CM (1993) Makaluvamines, Marine Natural Products, are Active Anti-Cancer Agents and DNA Topo II Inhibitors. Anti-Cancer Drug Design 8 333... [Pg.444]

Brown JM, Wang L-H (1998) Tirapazamine laboratory data relevant to clinical activity. Anti-Cancer Drug Design 13 529-539... [Pg.451]

Naylor MA, Stephens MA, Stratford IJ, Keohane A, O Neill P.Threadgill MD, Webb P, Fielden EM, Adams GE (1991) Aziridinyl nitropyrroles and nitropyrazoles as hypoxia-selective cytotoxins and radiosensitizers. Anti-Cancer Drug Design 6 151-167... [Pg.469]

D.K. Monteith, and A.A. Levin. 1997. Antisense oligonucleotide inhibitors for the treatment of cancer 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Design 12 383-393. [Pg.115]

C. M., Makaluvamines, marine natural products, are active anti-cancer agents and DNA topoisomerase II inhibitors, Anti-Cancer Drug Design, 8, 333, 1993. [Pg.538]

M. Ptak, A. Rahmouni, K. Mazeau, N. T. Thuong, M. Leng, Anti-Cancer Drug Design... [Pg.555]

Han H, Hurley LH. 2000. G-quadruplex DNA a potential target for anti-cancer drug design. Trends Pharmacol. Sci. 21 136—42... [Pg.380]

Ueda, K., Yoshida, A., and Amachi, T. (1999) Recent progress in P-glycoprotein research. Anti-Cancer Drug Design, 14, 115-121. [Pg.256]

Spicer JA, Finlay GJ, Baguley BC, Velea L, Graves DE, Denny WA (1999) Anti-Cancer Drug Design 14 37... [Pg.85]

A Kamal, K Atchison, M Daneshtalab, RG Micetich. Synthesis of podophyUotoxin congeners as potential DNA topoisomerasell inhibitors. Anti-Cancer Drug Design 10 545-554, 1995. [Pg.622]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...